Choose between two single-use and biocompatible tubing modules to be connected to the CliniMACS Prodigy Tubing Set, e.g. the CliniMACS Prodigy Tubing Set TS 520.
The CliniMACS Flexible Formulation Set is equipped with a waste bag (500 mL), two QC bags (20 mL), and ten lines for sterile connection of individual product containers.
The CliniMACS Formulation Set is equipped with a waste bag (250 mL), four 50 mL product/QC bags, and four 500 mL product/QC bags.
Choose between two single-use and biocompatible tubing modules to be connected to the CliniMACS Prodigy Tubing Set, e.g. the CliniMACS Prodigy Tubing Set TS 520.
The CliniMACS Formulation Set consists of sealed pre-assembled tubing pack for sampling, formulation, and filling. The set is suitable for both fresh or frozen product strategies and is equipped with a waste bag and 8 EVA product bags.
The CliniMACS Flexible Formulation Set gives you the freedom to connect up to ten product containers that perfectly meet the needs of your individual process. The set is equipped with a waste bag and two QC bags. Ten lines allow for sterile connection of different sizes of EVA product bags, cell transfer or culture containers, and the MACSQuant Tyto Cartridge.
The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.
In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g., for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.
In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval.
CR/GMP products are for ex vivo cell processing only, and are not intended for human in vivo applications. CR/GMP products are designed, manufactured and tested under an ISO 13485 quality management system and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The manufacturing and testing of CR/GMP products of biological origin are in compliance with EP chapter 5.2.12 for “Raw materials of biological origin for the production of cell-based and gene therapy medicinal products”.
You have previously chosen International as your location.
What do you want to do?